key: cord-0687591-nivawqjb
authors: Peterson, Derick R; Baran, Andrea M; Bhattacharya, Soumyaroop; Branche, Angela R; Croft, Daniel P; Corbett, Anthony M; Walsh, Edward E; Falsey, Ann R; Mariani, Thomas J
title: Gene Expression Risk Scores for COVID-19 Illness Severity
date: 2021-08-24
journal: bioRxiv
DOI: 10.1101/2021.08.24.457521
sha: 05efcc7bec50d59606933237ea17e49808560786
doc_id: 687591
cord_uid: nivawqjb

BACKGROUND: The correlates of COVID-19 illness severity following infection with SARS-Coronavirus 2 (SARS-CoV-2) are incompletely understood. METHODS: We assessed peripheral blood gene expression in 53 adults with confirmed SARS-CoV-2-infection clinically adjudicated as having mild, moderate or severe disease. Supervised principal components analysis was used to build a weighted gene expression risk score (WGERS) to discriminate between severe and non-severe COVID. RESULTS: Gene expression patterns in participants with mild and moderate illness were similar, but significantly different from severe illness. When comparing severe versus non-severe illness, we identified >4000 genes differentially expressed (FDR<0.05). Biological pathways increased in severe COVID-19 were associated with platelet activation and coagulation, and those significantly decreased with T cell signaling and differentiation. A WGERS based on 18 genes distinguished severe illness in our training cohort (cross-validated ROC-AUC=0.98), and need for intensive care in an independent cohort (ROC-AUC=0.85). Dichotomizing the WGERS yielded 100% sensitivity and 85% specificity for classifying severe illness in our training cohort, and 84% sensitivity and 74% specificity for defining the need for intensive care in the validation cohort. CONCLUSION: These data suggest that gene expression classifiers may provide clinical utility as predictors of COVID-19 illness severity.

. CC-BY-NC-ND 4.0 International license available under a (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made

The copyright holder for this preprint this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.24.457521 doi: bioRxiv preprint Introduction 1 In December 2019 a novel coronavirus, SARS-CoV-2, was identified in China as a cause of 2 severe pneumonia with explosive human-to human transmission [1] . Illness due to SARS-CoV-2 3 has been designated COVID-19, and on March 11, 2020, the World Health Organization 4 officially declared SARS-CoV-2 a pandemic. To date there have been over 100 million infections 1 using the nonparametric Kruskal-Wallis test, and binary variables by Fisher's exact test. We 2 tested for differential expression by COVID-19 severity using the nonparametric Wilcoxon rank 3 sum test. To allow adjustment for important clinical covariates, we fit semi-parametric Cox 4 proportional hazards models for normalized gene expression as a function of severe vs non-5 severe COVID-19, adjusted for race, sex, BMI, days since symptom onset, and library size. The 6 Benjamini-Hochberg procedure was used to control the False Discovery Rate (FDR). Pathway 7 analysis of significantly differentially expressed genes was performed using ENRICHR [13] . . CC-BY-NC-ND 4.0 International license available under a (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made

The copyright holder for this preprint this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.24.457521 doi: bioRxiv preprint 8 To perform an independent validation of our risk score, we use a dataset from Overmyer et al.

1 [14] . There were some notable differences between the validation data and our training dataset, 2 including a different definition of severity in the outcome (ICU vs non-ICU) and use of a different 3 normalization for the gene expression data (TPM). Of the 18 genes used in our risk score, 2 4 were missing in the validation data. We imputed data for these 2 genes via multiple linear 5 regression with coefficients estimated by regressing each on the 16 non-missing CPM-6 normalized log gene expression values in the training data. We standardized the TPM-7 normalized validation gene expression data using means and SDs estimated from the training 8 data, and then applied the risk score coefficients from the training data to construct a risk score 9 for each validation subject. Apparent miscalibration required choosing a different WGERS 1 0 threshold for the validation data due to gene expression measures being generally lower in the 1 1 validation data compared to the training data. An ROC curve with associated AUC was used to 1 2 assess the performance of the risk score in the validation data. . CC-BY-NC-ND 4.0 International license available under a (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made

The copyright holder for this preprint this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.24.457521 doi: bioRxiv preprint

Between April 30th and June 29th 2020, 58 participants with PCR documented COVID-19 2 illnesses were enrolled from inpatient and outpatient settings. Of these, 3 participants did not 3 have blood samples collected and 2 did not meet inclusion criteria, leaving 53 participants for 4 RNA sequencing analysis. Illnesses were adjudicated as 20 severe and 33 non-severe (14 mild 5 and 19 moderate). This categorization was consistent with the severity separation in the NEWS 6 (Supplemental Figure S1 ). Two severely ill participants received one dose of Remdesivir prior to (Table 1) : white non-Hispanic comprised 93% mild vs 50-58% 1 4 moderate-severe (p=0.02), and median time from symptom onset to enrollment was 4 days 1 5 among mild, 9 days among moderate, and 6.5 days among severe (p=0.047, due to 1 6 heterogeneity among non-severe). The median age of participants was 62 years with 53% of 1 7 them being male. As expected, dyspnea, hypoxemia, the presence of infiltrates, and use of 1 8 supplemental oxygen were more common in moderate and severe, compared to mild illness. All

severely ill patients required intensive care; 15 were enrolled in the ICU and 5 were moved to 2 0 ICU within 48 hours of blood sampling. All severely ill participants required supplemental 2 1 oxygen; 12 (60%) were mechanically ventilated, one was supported with ECMO and survived, 2 2 13 (65%) required vasopressor support and one subject died. Median NEWS were different 2 3 between the 3 groups ( Figure S1 ). Inflammatory markers were not available for most outpatients 2 4 but were notably elevated in those hospitalized with moderate to severe disease. (Table 1) 2 5 2 6 . CC-BY-NC-ND 4.0 International license available under a (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made

The copyright holder for this preprint this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.24.457521 doi: bioRxiv preprint 1 0

Blood gene expression profiling from SARS-CoV-2 positive cases (n=53) was completed by 1 standard mRNA sequencing (RNAseq) of globin mRNA-reduced RNA isolated from whole blood 2 at the time of recruitment. On average 58 ± 6 million reads were generated from each of the 3 cDNA libraries, with a mapping rate of 94.2 ± 0.6% and transcriptome coverage of 4 41.3 ± 1.3% (Supplemental Figure S2 ). Exploratory Principal Components Analysis suggested 5 similar patterns of gene expression might be shared by participants with mild and moderate 6 illness, but appeared distinct from those with severe illness ( Figure 1A ). Statistical analysis for 7 differential gene expression confirmed significant differences when comparing mild vs severe, 8 and moderate vs severe, but not mild vs moderate COVID ( Figure 1B ).

We next tested for differences in gene expression when comparing participants with severe 1 1 (n=20) vs non-severe illness (n=33), pooling the 14 mild and 19 moderate cases. We tested for 1 2 differential gene expression without (univariate) and with adjustment for variables potentially 1 3 associated with severe outcome (race, sex, BMI), the number of days since onset of symptoms, 1 4 and library size ( Figure 1C and Supplemental Table 1 ). These analyses identified 6483 (46% of 1 5 tested) and 8435 (59% of tested) differentially expressed genes, with and without multivariate 1 6 adjustment, respectively. Table S2 ). Activated pathways included a number associated with infectious 2 3 diseases as well as TNFα and NFkB signaling. Notably, there was also evidence for significant 2 4 upregulation of genes associated with platelet activation and coagulation. Among pathways 2 5 associated with downregulated genes in severe COVID were multiple pathways involved in 2 6 . CC-BY-NC-ND 4.0 International license available under a (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 1 1 general host RNA metabolism as well as multiple pathways specifically associated with T cell 1 regulation, including Th2 and Th17 differentiation. The most significantly downregulated 2 pathway was associated with HSV1 infection.

Given the substantial number of differentially expressed genes when comparing severe vs non-5 severe COVID, we investigated the ability of gene expression patterns to discriminate severe 6 illness. Gene-specific thresholds for univariate AUC and magnitude change were chosen via the 7 cross-validation procedure and used to produce an 18 gene weighted gene expression risk curve also was used to select a risk score threshold (-1.04) with 95% sensitivity and 88% 1 2 specificity, which corresponded with apparent (non-cross-validated) sensitivity of 100%, 1 3 specificity of 85%, and error rate of 9% (5/53), represented via the WGERS distributions for the 1 4 training data ( Figure 4A ). All 5 misclassified participants had moderate illness ( Figure 4B ).

We next identified an independent validation data set describing peripheral blood-based gene . CC-BY-NC-ND 4.0 International license available under a (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made CC-BY-NC-ND 4.0 International license available under a (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made

The copyright holder for this preprint this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.24.457521 doi: bioRxiv preprint 1 6

In summary, we found a large number of differentially expressed genes in the peripheral blood 2 that distinguished those with severe COVID-19 illness from those with mild or moderate 3 disease. These data could be used to identify potential targets for interventions, as well as to 

The manuscript represents original work that is not currently under consideration elsewhere. . CC-BY-NC-ND 4.0 International license available under a (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made CC-BY-NC-ND 4.0 International license available under a (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made

The copyright holder for this preprint this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.24.457521 doi: bioRxiv preprint 2 3 . CC-BY-NC-ND 4.0 International license available under a (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made

The copyright holder for this preprint this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.24.457521 doi: bioRxiv preprint . CC-BY-NC-ND 4.0 International license available under a (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made

The copyright holder for this preprint this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.24.457521 doi: bioRxiv preprint

A Novel Coronavirus from Patients with Pneumonia in 2 China

Clinical Characteristics of Coronavirus Disease

Epidemiological and clinical characteristics of 99 cases of 6 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Characteristics of and Important Lessons From the Coronavirus 9 Disease 2019 (COVID-19) Outbreak in China

(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is madeThe copyright holder for this preprint this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.24.457521 doi: bioRxiv preprint 2 7 COVID, with and without adjustmentfor pre-specified covariates: race, sex, BMI, days 1 since symptom onset, and library size. (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is madeThe copyright holder for this preprint this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.24.457521 doi: bioRxiv preprint 3 0 (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is madeThe copyright holder for this preprint this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.24.457521 doi: bioRxiv preprint